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Abstract
Background—Maladaptive left ventricular hypertrophy (LVH) remains a prevalent and highly
morbid condition associated with end-stage heart disease. Originally evaluated in the context of
bone development, periostin is important in endocardial cushion formation and has recently been
implicated in heart failure. Because of its potential role in cardiovascular development, we sought
to establish the role of periostin after relief of pressure overload in animal and human models.
Methods—Pressure overload induction of LVH was performed by minimally invasive aortic arch
banding of C57Bl6 mice. Bands were removed 1 month later to allow regression. Cardiac tissue
was procured in paired samples of patients receiving LV assist devices (LVAD), with subsequent
reanalysis at the time of explant for transplantation.
Results—One week after debanding, heart weight/body weight ratios and echocardiography
confirmed decreased LV mass relative to hypertrophied animals. Gene and protein expression of
periostin was measured by real-time polymerase chain reaction and Western blot, and was
similarly decreased compared with LVH mice. Immunohistochemical localization of periostin
showed it was exclusively in the extracellular matrix of the myocardium. The decrease in periostin
with pressure relief paralleled changes in interstitial fibrosis observed by picrosirius red staining.
Corroborating the murine data, periostin expression was significantly reduced after LVAD-
afforded pressure relief in patients.
Conclusions—Periostin is closely associated with pressure overload-induced LVH and LVH
regression in both animal and human models. The magnitude of expression changes and the
consistent nature of these changes indicate that periostin may be a mediator of cardiac remodeling.
Left ventricular hypertrophy (LVH) remains a highly prevalent and a powerful independent
risk factor for cardiovascular death and disease in North America [1]. Initially viewed as
beneficial, LVH transitions to a maladaptive phase and leads to clinical heart failure.
Although many have studied the remodeling process, few have focused on the changes that
occur when a failing heart recovers.
We recently described the physiologic and genomic changes that occur in a murine model of
pressure overload and subsequent relief [2]. First, we demonstrated that increased LV mass
associated with aortic constriction is largely reversible. Second, during the processes of
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hypertrophic progression and regression, we identified several dominant functional groups
of genes that were independently expressed during LVH progression and regression.
Notably, we observed an abundance of genes that control the development and function of
the extracellular matrix (ECM). One gene in particular, periostin, stood out from this group
for its previous genomic associations with both ventricular hypertrophy [3] and heart failure
[4].
Periostin is an ECM protein that derived its name from studies of bone development in
which it localized to both cortical bone periosteum and the periodontal ligament. Its first
association with the heart was described in the context of endocardial cushion formation and
heart valve formation [5]. Subsequently, periostin has been identified as a secreted factor
within the ECM. It is believed to have a strong relationship with fibrosis and ECM
metabolism in a variety of disease states, including cardiovascular disease and cancer [6].
In this context, we sought to determine the role of periostin in cardiac remodeling. Using our
existing models for pressure overload and relief in both mice and humans, we demonstrate
that periostin expression and patterns of fibrosis are closely related to pressure overload, and
that in suitable conditions, periostin expression, LVH, and fibrosis can be significantly
reversed.
Material and Methods
Surgical Model and Experimental Design
In accordance with both an institutionally approved Institutional Animal Care and Use
Committee protocol and National Institutes of Health guidelines, 10-week-old C57Bl6 male
mice (n = 60) were randomly assigned to one of three groups: sham, band, and deband (Fig.
1).
Mice in the sham and band groups underwent minimally invasive transverse aortic banding
as previously described [7]. Briefly, animals were anesthetized using inhaled isoflurane by
face mask. A midline neck incision was used to approach the anterior mediastinum. The
transverse arch was identified, and a constrictive band was placed and tightened to the
approximate diameter of a 27-gauge needle. The only difference between sham and band
groups was that the constrictive band was not tightened in the sham animals. Adequate
placement of the band was verified by evaluation of carotid Doppler imaging before and
after placement of the aortic band. Adequate banding was accepted when the Doppler
velocity ratio doubled from right to left carotid arteries.
Animals in the deband group underwent an initial procedure identical to the band animals.
At 4 weeks, the aortic band was removed [7]. Efficiency of debanding was verified by
carotid Doppler with normalization of carotid velocities. Deband and sham deband animals
were sacrificed 1 week after the deband procedure for all evaluations except histology,
where animals were sacrificed both at 1 and 4 weeks after debanding.
Transthoracic Echocardiography
Transthoracic echocardiography was performed using the Vevo 660 High Resolution
Biomicroscopy System equipped with a 30-Mhz transducer (Visual Sonics, Toronto, ON,
Canada). During examination, mice were anesthetized with 1% to 1.5% inhaled isoflurane.
Depth of anesthesia was standardized by recording images at heart rates of 480 to 520 beats/
min. Images were recorded in all animals preoperatively, at 2 and 4 weeks after banding,
and at 1 week after debanding. Two technicians, blinded to the animals’ experimental status,
performed examinations and measurements.
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At time of sacrifice, hearts were rapidly excised and the LV apices were sectioned and flash
frozen in liquid nitrogen for gene array analysis. Additional animals allocated to histologic
analysis were perfused with phosphate-buffered saline, followed by 10% formalin, fixed
overnight in formalin, and then processed for histologic analysis using periodic acid Schiff
staining. The cardiomyocyte cross-sectional area was measured using ImageJ 1.38j software
(National Institutes of Health, Bethesda, MD) [8].
RNA Preparation and Real-Time Polymerase Chain Reaction
LV apices were homogenized in 0.5 mL of ice-cold Trizol solution (Sigma, St Louis, MO)
using a bead mill homogenizer (Retsch, Newtown, PA). RNA was isolated using the
standard Trizol procedure, with additional steps for removal of DNA and fibrous tissue.
Purity of RNA was verified by using a 260/280 ratio of 1.95 or higher. An Agilent
BioAnalyzer 2100 instrument (Agilent Technologies Inc, Santa Clara, CA) was used to
verify RNA integrity for all samples. Real-time polymerase chain reaction (PCR) was
performed using TaqMan primers and probes (Applied Biosystems International, Foster
City, CA).
Western Blot
Protein fractions were isolated in ice-cold lysis buffer during Dounce homogenization.
Concentrations were determined using the Bradford assay. Protein fractions were denatured
in loading buffer, and 30 μg of each sample was loaded into alternating lanes for gel
electrophoresis. Membrane transfer was performed overnight, and rabbit antimouse antibody
was used to probe for periostin. Glyceraldehyde-3-phosphate dehydrogenase was used as the
loading control.
Immunohistochemistry
Mouse hearts were perfused with formalin and ethanol at the time of euthanasia, fixed, and
then histologically processed according to institution routine, including picrosirius red
staining. Formalin-fixed slide blanks were stained with monoclonal antibody to periostin
and developed with 3,3′-diaminobenzidine for light microscopic evaluation. Slides were
scanned using a ScanScope CS slide scanner using a ×40 objective (Aperio, Vista, CA).
Images were cropped to remove valvular tissue and were processed using ImageJ 1.4.1
software. Color thresholding was completed using a custom Java script.
Human Tissue Procurement
Human myocardial tissue specimens were obtained from patients with end-stage heart
disease who were on the transplant waiting list and required LV assist device (LVAD)
support. Procurement protocols were approved by the University of North Carolina
Institutional Review Board, and patients were appropriately consented before procurement.
Briefly, LV apical cores were immediately passed off the table, cut into several specimens,
and frozen in liquid nitrogen. At the time of subsequent transplantation, LV specimens from
the explanted hearts were similarly cut and frozen in liquid nitrogen. Processing of these
tissues was performed as described above.
Statistical Methods
All physiologic data are presented as mean ± standard error (SE), except where noted. Real-
time PCR data were log-transformed before comparison. All comparisons of physiologic
data were performed using two-tailed, type 3 or type 1 t tests. Significance was established
at the 95% confidence interval (CI).
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Periostin Expression Increases With Hypertrophy and Decreases With Regression
We have previously demonstrated the utility of minimally invasive transverse aortic arch
banding and debanding to characterize LVH progression and regression [2, 7]. To
functionally validate our periostin studies, we used transthoracic echocardiography to
demonstrate within this cohort of animals that banding caused pressure-induced LVH that
was reversed 1 week after debanding (Table 1).
Real-time PCR was used to verify expression levels of periostin in cardiac tissue before and
after induction of pressure overload, and after relief of pressure overload (Fig. 2).
Comparatively, pressure overload was associated with a 20-fold increase in expression over
baseline (19.9 ± 7.1 vs 1.20 ± 0.34, p < 0.05), and after 1 week of relief from overload,
ventricular expression was significantly decreased to only a 5-fold increase from baseline
(4.94 ± 1.25 vs 19.9, p < 0.05). This rise and fall in periostin expression with pressure
overload and relief correlates with previously documented changes in the hypertrophic
markers β-myosin heavy chain and skeletal muscle α-1 actin. Notably, the deband group did
express greater amounts of periostin than the sham group.
Western blot analysis of periostin protein expression demonstrated a similar trend: increased
expression with pressure overload was subsequently decreased after relief of pressure
overload. Densitometry confirmed significantly increased quantities of periostin in the
pressure overload animals relative to baseline (38,300 ± 5,600 vs 20,300 ± 700, p < 0.05).
Levels of periostin were significantly less in the relief group (18,300 ± 5,000 vs 38,300, p <
0.05). Unlike the trends with gene expression, differences between the sham and deband
groups were not evident at the protein level.
Immunohistochemical analysis was used to identify periostin in both hypertrophied and
regressed animals. Sample cross-sectional images demonstrated expression trends similar to
those seen with real-time PCR. There was a significant increase in periostin deposition with
hypertrophy that decreased with regression. As with the real-time PCR, periostin staining
was greater in the deband group relative to the sham group. Curiously, periostin staining was
most prominent in the interventricular septum.
Periostin and Fibrosis
Picrosirius red staining revealed the pattern of collagen deposition in hypertrophy and
regression mimicked that observed with periostin (Fig. 3). At the level of the whole heart in
cross-section, collagen was increased in pressure overload and decreased in relief of
pressure overload. As with periostin, there was a predominance of collagen staining in the
interventricular septum relative to the other parts of the heart and LV. Automated image
analysis of whole cross-sections of heart was used to quantify this finding, with pressure
overloaded hearts demonstrating approximately 2.5 times as much collagen as those of sham
or relief hearts. No significant difference in collagen staining was observed between
regressed and sham hearts when automated analysis techniques were used.
Higher magnification showed that the bulk of the increased staining of collagen and
periostin occurred in both perivascular regions and in the myocardial interstitium (Fig. 3C)
Slides scanned using a ×20 objective showed both collagen and periostin staining strongly in
the media and adventitia, and then radiating outward into the interstitium. Although minimal
staining occurred in the perivascular space of sham specimens, similarly sized vessels in
pressure overload specimens showed dramatic increases. In relief of pressure overload,
collagen and periostin were both less present in those same locations, with no apparent
redistribution of staining, although still more prominent than in sham specimens.
Stansfield et al. Page 4













Periostin is Overexpressed in the Failing Human Heart
To evaluate our findings in the context of a human model, we used pressure-overloaded
hearts from patients with heart failure who were undergoing LVAD placement (Jarvik 2000,
Jarvik Heart, Inc, New York, NY). Cardiac tissue was obtained at time of LVAD placement
and at time of transplant. Patients all had stage IV heart disease and were status IB on the
transplant wait list. The mean age was 40, with one 21-year-old outlier. Two patients had
idiopathic cardiomyopathy, 1 patient had ischemic cardiomyopathy, and another had a
familial cardiomyopathy. All patients had echocardiographically determined ejection
fractions of 0.10 to 0.20 before and after VAD placement.
One patient died of a hemorrhagic stroke before transplant, but survived for organ donation;
post-VAD cardiac tissue was obtained at this time. The mean time with VAD was 131 ± 115
days (range, 32 to 296 days).
All pairs of samples indicated significantly decreased periostin expression by Western blot
after mechanical offloading (Fig. 4). The only exception was the patient with ischemic
cardiomyopathy who had approximately equivalent expression, and who waited the longest
for transplant at 296 days. The 3 patients who received a transplant are all alive at the time
of this report, with a mean survival greater than 2 years.
Comment
Clinically, myocardial remodeling is any change in the size, shape, or function of the LV
such that cardiovascular survival is altered. Although symptoms and LV ejection fraction are
commonly used as surrogates because they are readily quantifiable, both are relatively poor
indicators of survival [9]. Presently, only two classes of medications, namely, β-blockers
and angiotensin-converting enzyme inhibitors, have been shown to significantly improve
remodeling and survival beyond their effects on symptoms or blood pressure. By studying
the remodeling process explicitly, the goal of our laboratory has been to identify additional
potential mediators of regression, or beneficial remodeling.
We have shown the expression pattern of periostin in both experimental and clinical
progression and regression of ventricular hypertrophy. Is periostin simply a marker of
hypertrophy or does it have a formal role in the remodeling process? We recognize the
observational limitations of our study and acknowledge that the changes in periostin may be
a phenomenon occurring in parallel with changes in hypertrophy.
We believe, however, that periostin is more than an innocent bystander. Indeed, periostin is
positioned as a key ECM protein that likely serves several beneficial roles in the
development and maintenance of a well-functioning ventricle. We observed significant
tissue levels of periostin in all animals. This is consistent with previous data demonstrating
periostin is active developmentally in the endocardial cushion formation [5]. In addition, a
recent study showed an increased rate of ventricular rupture after myocardial infarction in
periostin knockout (Pn−/−) mice [10]. Collectively, these studies and ours demonstrate that
periostin is an integral part of a well-functioning myocardium.
Teleologically, as with LVH, some periostin is good, whereas overexpression can allow for
maladaptive LVH and heart failure. In pressure overload, periostin is highly over-expressed
and is associated with numerous cardiovascular pathologies. Principally, there is an
increased volume of collagen deposition and fibrosis within the myocardium and in
perivascular tissues. Increased collagen and fibrotic proliferation is believed to impair
ventricular compliance and lead to diastolic dysfunction [11]. This may have contributed to
the decreased contractility that we observed in our pressure overload animals [7].
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Correspondingly, the increased perivascular expression of periostin and collagen that we,
and others, have observed is believed to impair nutrient and oxygen delivery to the
myocardium [12]. It is likely that this further diminishes the ability of the myocardium to
respond to the increased work of pressure overload.
Although we observed a diffuse increase in periostin expression and collagen deposition
across the entire LV in our model, there was a significant predominance of expression in the
interventricular septum. This may be due to regional differences in strain experienced by the
LV component of the septum, a phenomenon well documented in humans but not yet in
mice [13].
Importantly, in our series of regression experiments, we were able to successfully
demonstrate that periostin expression decreased with relief of pressure overload. It is
unknown whether the process of regression actively induced metabolism of periostin, or
whether the natural tissue half-life of periostin is relatively short and dependent on
continued expression. In contrast, collagen is believed to be a more durable product in
fibrosis, and yet collagen was similarly less present in hearts that had experienced relief of
pressure overload. This suggests that an active process within the ECM of the myocardium
contributed to the metabolism of collagen. Previous authors have speculated that fibrosis and
collagen deposition significantly lessen the ability of a ventricle to undergo regression of
hypertrophy [14]. We believe our findings demonstrate that collagen-based changes in the
ECM of the LV wall associated with LVH are, in fact, reversible.
Our echocardiographic studies demonstrated that 4 weeks of pressure overload resulted in
increased chamber dimension and decreased LVEF, both of which contribute to heart failure
[7]. In regression, we observed a reversal of both phenomena, indicating rescue. Although
periostin is believed to be important in establishing and maintaining a healthy and functional
ECM, it is likely that in the pathophysiology of pressure overload, it contributes to the
dysfunction that leads to features of heart failure. Initial studies strongly linked gene
expression of periostin with the progression of heart failure [4]. More recent studies with
Pn−/− mice have demonstrated that if mice survive myocardial infarction, then the absence
of periostin is associated with improved long-term myocardial function [10], suggesting that
the presence of periostin may significantly impair recovery from an ischemic event.
In addition, studies of periostin in cancer have shown that periostin is highly associated with
tissue invasion and metastasis. It is typically expressed at border zones, and periostin
expression by tumor cells has been directly correlated with loss of host tissue integrity and
tumor in-growth [6, 15]. Although the mechanism of action remains to be determined, it is
possible that the characteristics that lead to tissue invasion are similar to those that facilitate
ventricular susceptibility to wall stress and pressure overload. Importantly, our findings,
including those in our heart failure patients with bridge to transplant VADs, indicate that the
LV dilatation and wall thickening associated with pressure overload are partly reversible and
that this reversal occurs in an environment of decreased periostin expression.
We fully acknowledge several limitations of the study. Our mouse model of pressure
overload and relief is most analogous to aortic valve replacement therapy for aortic stenosis.
Our human model of pressure overload is necessarily quite different, in that there are no
conditions in which heart tissue may be readily removed from healthy individuals. We
believe that our current model, using pressure overloaded, failing hearts and then resampling
after ventricular assist, is the closest human model available that affords ready access to
tissue.
A related limitation is that the fibrosis that occurs in adult hearts from pressure overload is
typically the result of longstanding pathology. In the mice, there is an acute onset of pressure
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overload, with a relatively rapid progression of hypertrophy and even failure. Despite these
differences, both groups showed significant decreases in periostin expression with relief of
pressure overload, further reinforcing our hypothesis that excessive periostin expression is
associated with ventricular dysfunction and that functional improvement is associated with
decreased periostin expression.
In summary, periostin is significantly over-expressed in conditions of myocardial pressure
overload and significantly under-expressed in relief of pressure overload. These expression
changes correspond closely with ventricular function, myocardial hypertrophy, and
ventricular fibrosis. Although mechanisms of action are yet to be determined, a variety of
reports suggest that periostin, although necessary developmentally, has significant adverse
effects during pathologic over-expression. Specifically, ventricular remodeling is associated
with greater dysfunction during periostin expression, and pressure offloading and functional
improvement are linked with decreased tissue levels of periostin. We believe our data
support further studies that target periostin as a means of therapy for fibrotic myocardial
disease.
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Overview of mouse experiments and timeline for human tissue procurement. (VAD =
ventricular assist device.)
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Periostin expression in experimental pressure overload and relief. (A) Mouse hearts were
procured at the respective times with analysis for real-time polymerase chain reaction of
periostin expression relative to 18S rRNA (n = 5,4, and 4 for sham, band, and deband mice;
*band vs sham, p = 0.002; †deband vs band, p = 0.034). (B) Western blot of periostin protein
expression is corroborated by (C) densitometry (n = 2, 3, and 3 for sham, band, and deband
mice; *band vs sham, p = 0.042; †deband vs band, p = 0.038.) The error bars in (A) and (C)
reflect the standard error. (D) Immunohistochemistry is shown for periostin staining.
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Periostin and fibrosis. (A) Mouse ventricles were stained with picrosirius red to detect
collagen deposition at each respective time. (B) Immunohistochemical quantification of
whole ventricle collagen staining (n = 4, 13, and 9 for sham, band, and deband; *band vs
sham, p = 0.0001; †band vs deband, p = 0.0002). (C) Higher power (×20) objective of
collagen-stained sections. (D) Immunohistochemical staining for periostin expression.
(Scale bar for C and D = 100 microns.)
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Western blot of periostin in matched human tissue samples before and after treatment with
ventricular assist device (VAD). Densitometry of protein expression levels relative to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; n = 4 paired samples; *post-VAD vs
pre-VAD, p = 0.077).
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